

# **History of genome editing: From meganucleases to CRISPR**

Simon E. Tröder<sup>1,2</sup> and Branko Zevnik<sup>1,2\*</sup>

<sup>1</sup> in vivo Research Facility, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

<sup>2</sup> Cologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany

\*Corresponding author

E-mail: [branko.zevnik@uk-koeln.de](mailto:branko.zevnik@uk-koeln.de)

## **Abstract**

CRISPR-mediated genome editing has undoubtedly revolutionized genetic engineering of animals. With the ability for virtually unlimited modification of almost any genome it is easy to forget which amazing discoveries paved the way for this groundbreaking technology. Here, we summarize the history of genome editing platforms, starting from enhanced integration of foreign DNA by meganuclease-mediated double strand breaks to CRISPR/Cas9, the leading technology to date, and its re-engineered variants.

## **Introduction**

Genetic engineering of organisms is the key to biomedical and biotechnological research. The ultimate tool would allow precise and unlimited modification of any given nucleic acid sequence in a simple fashion. With the rise of genome editing we have never been closer to accomplishing this goal. This review will summarize the exciting key developments leading to the breakthrough of genome editing with a particular focus on CRISPR-based tools as the leading technology to date.

Genetic engineering started with transgenesis, the deliberate transfer of genetic information from one organism to another. In 1974, Rudolf Jaenisch demonstrated that viral DNA injected into blastocysts led to stable integration in the genome of mice<sup>1</sup>. This is considered to be the first transgenic animal generated. The term “transgenic” though was introduced only in 1981 by Gordon and Ruddle when they and others showed that injection of DNA into pronuclei of murine zygotes conferred stable germline transmission of the genetic modification to the next generation<sup>2-5</sup>. Although integration occurred randomly and without copy number control, researchers were able to establish a stable genetically engineered mouse

line for the first time. At the same time, two groups independently isolated pluripotent mouse embryonic stem cells (ESC)<sup>6, 7</sup> which were able to colonize the entire embryo, including the germ line, upon injection into host blastocysts<sup>8</sup>. In these cells, Oliver Smithies and Mario Capecchi employed the process of homologous recombination to inactivate a specific gene in the mouse<sup>9, 10</sup>. This groundbreaking discovery, termed gene targeting, allowed site-directed modification of the genome for the first time and earned Mario Capecchi, Martin Evans and Oliver Smithies the 2007 Nobel Prize in Physiology or Medicine. By the additional coupling with a site-specific recombination system (i.e. Cre-lox), the group of Klaus Rajewsky expanded the scope of gene targeting in a time and cell type specific fashion and this approach soon became the gold standard for genome engineering in mice for the next decades<sup>11, 12</sup>. Despite its undeniable power, the homologous recombination approach exhibited several limitations. Firstly, the poor integration frequency at a specific site in zygotes required the time-consuming detour through ESC targeting and subsequent injection into blastocyst for the generation of genetically modified (GM) mice<sup>13</sup>. Secondly, due to the low integration frequency, a selectable marker (often an antibiotic resistance gene) was required to determine which ESCs integrated the DNA. The use of this marker would leave undesired genetic material that required subsequent removal to avoid altering expression of the gene<sup>9, 10</sup>. Finally, the approach was largely limited to mice due to the lack of protocols for ESC isolation or the failure to isolate such cells in most other species<sup>14</sup>.

### **The rise of genome editing (1985 – 2013)**

How could these limitations be overcome? One important step was the discovery that double strand breaks (DSB) dramatically enhance the integration of foreign DNA in mammalian cells<sup>15-17</sup>. These studies employed the meganuclease I-SceI to induce DSB in the

genome of mouse cells. DSBs subsequently recruit the endogenous repair machinery and are either repaired by end joining pathways, which can result in random insertions and deletions (INDELs) or, if a DNA repair template is provided, by homology-directed repair (HDR) pathways (Figure 1). Meganucleases are low frequency cutters with a recognition sequence of typically 20-30 bp discovered in yeast in 1985<sup>18</sup> (Figure 2). They are involved in gene conversion processes like duplication and have now been identified in many microbial genomes<sup>19</sup>. Although hundreds of naturally occurring meganucleases exist, their fixed recognition sequence drastically limited the choice of targetable loci. Subsequent re-engineering of the DNA recognition site led to more flexibility and enabled site directed genome modification in mammalian cells, mice and rats<sup>20-22</sup>. Yet, reconfiguring the structure of an entire protein for every single target site was tedious.

What if there was a protein motif which has already naturally evolved to bind various different nucleotide sequences? Zinc fingers are small protein motifs with sequence specific DNA binding capacity. They were first discovered in 1985 as part of a transcription factor in frog oocytes but are in fact present in many species, including humans<sup>23, 24</sup>. They were termed zinc fingers as they are stabilized by a zinc ion in order to bind their DNA target. In contrast to other DNA binding motifs, they utilize a cascade of modules in which a few key residues in the protein mediate recognition. Each module harbors a DNA binding motif specific to three consecutive base pairs of the target sequence. This modular structure makes them highly versatile in binding specific DNA sequences of various lengths<sup>24</sup>. In 1996, researchers fused these zinc finger modules to the DNA cleavage domain of the restriction enzyme FokI in order to generate a programmable nuclease, termed Zinc Finger Nucleases (ZFN)<sup>25</sup>. The ease of inducing DSB by ZFN subsequently led to a number of applications in biotechnology and biomedicine. Pilot experiments in 2001 in *Xenopus* oocytes demonstrated the feasibility of enhanced HDR by ZFN<sup>26</sup>. Shortly thereafter, the approach was optimized and applied to other organisms, like *Drosophila* and human cells, and also employed therapeutically to correct the

human SCID mutation *in vitro*<sup>27-29</sup>. The latter study introduced the term “genome editing” in 2005 for the first time as an analogy to word processing<sup>29,30</sup>.

DSB, like those caused by ZFNs, can be repaired by HDR if a repair template is provided. That was how Knock-Out (KO) and Knock-In (KI) mutations have been generated with genome editing. However, most DSB in vertebrate cells are repaired by error-prone end joining pathways which frequently result in INDELs and not by HDR. Inspired by previous work in lower organisms like flies, worms and plants, in 2008 three independent groups realized that one can utilize the thus far undesired INDEL mechanism to efficiently induce KOs in zebrafish and mammalian cells without the need of HDR with a repair template. This process was so efficient that no selection was needed<sup>31-33</sup>. A break-through for the generation of GM mammals came in 2009 when it was shown that microinjection of DNA or mRNA encoding for specific ZFNs in rat zygotes produced the first KO rats<sup>34</sup>. This technology was swiftly adapted to generate GM model organisms like mice and rabbits but also livestock animals like cattle and pigs (see Table S1 online for references).

Another major discovery in the field of designer nucleases arose with the construction of TALENs in 2010<sup>35, 36</sup>. Researchers realized that the DNA binding domain of ZFN can be exchanged with more flexible and easier to generate DNA binding modules. These modules originated from Transcription Activator–Like Effector (TALE) proteins discovered in plant pathogenic bacteria of the genus *Xanthomonas*. These bacteria utilize the sequence specific binding capacity of TALEs to manipulate the gene expression of the infected plant cell in their favor. Like zinc finger proteins TALEs possess a variable DNA binding domain. However, there is a simple code of recognition where one module in the protein corresponds to only one of the four nucleotides (A, T, C or G). Various combinations of these four modules can therefore target any DNA sequence. Furthermore, as only two amino acids are responsible for the nucleotide specificity, TALEs are easier to generate than are zinc finger proteins<sup>37</sup>. For genome editing, TALE Nucleases (TALEN) stem from the fusion of a sequence-tailored TALE DNA-

binding domain to the FokI endonuclease domain (analogous to that used for ZFN)<sup>35, 36</sup>. As the design and the generation of TALENs required less effort and was more flexible, they immediately started to replace ZFN for genome editing. Soon after their first application in cell culture, TALENs were used to modify the genomes of a number of model organisms including worms, zebrafish, frogs, rats, mice and rabbits. But they were also employed in live-stock like pigs, goats, sheep and cattle as well as non-human primates (see Table S1 online for references).

### **The history of CRISPR genome editing (1987 – 2013)**


What if there was a protein which has programmable DNA binding capabilities like TALE and zinc finger proteins but does not need time consuming construction of a new protein domain? Ideally, this protein would already even exist as a nuclease in nature. Unknowingly, such a system had already been discovered, one we now know as the CRISPR/Cas system in bacteria.

In the late 1980s, repeats were observed in the genome of *Escherichia coli* which, unlike typical tandem repeats, were separated by non-repeating spacer sequences<sup>38</sup>. The nature of these repeats remained elusive for more than a decade until improved sequencing technologies enabled the decoding of many other genomes. In 2000, Mojica and co-workers realized that these repeats are present in many other bacteria and virtually all archaea, which pointed to an important role for these elements<sup>39</sup>. In addition, these repeats were shown to be associated with conserved genes subsequently called CRISPR-associated or Cas genes, which are in fact naturally occurring endonucleases. This was also the first use of the term CRISPR for Clustered Regularly Interspaced Short Palindromic Repeats<sup>40</sup>. In 2005, three research groups independently demonstrated that the spacer sequences are identical to genomes from phages and other foreign genetic elements<sup>41-43</sup>. In 2007, the nature of CRISPR was finally proven, when

Horvath and co-workers demonstrated that infected bacteria incorporate spacers derived from phage which in turn directs the Cas protein to the genome of the invaders where it precisely cuts the phage DNA. The CRISPR/Cas system therefore provides a defense mechanism against infections, similar to the adaptive immune response known from higher organisms like mammals<sup>44</sup>. Soon after it became clear that so-called CRISPR RNA (crRNA) is transcribed from the spacer to guide the Cas protein to its target<sup>45</sup> and that the target is DNA<sup>46</sup>. A short sequence motif adjacent to the crRNA targeted sequence on the target DNA, termed the protospacer adjacent motif (PAM), was not only shown to be critical for cleavage but also responsible for self vs. non-self discrimination of the CRISPR system<sup>47-50</sup>. In addition, it was shown that in a certain CRISPR system only a single Cas protein, that is Cas9, confers DNA cleavage<sup>49, 51</sup> and trans-activating crRNAs (tracrRNAs), which play a role in the maturation of crRNA, are critical for its activity<sup>52</sup>. Undoubtedly, the most important experiments were conducted independently by the group of Emmanuelle Charpentier in collaboration with Jennifer Doudna and almost in parallel by the group of Virginijus Siksnys. They demonstrated that the CRISPR/Cas9 system can be reconstituted *in vitro* and programmed to target desired sequences in other species which proved its applicability as a programmable nuclease for genome editing<sup>49, 53</sup>. Charpentier and Doudna, in conjunction with Martin Jinek, also simplified the system when they fused the crRNA and tracrRNA into a single guide RNA (sgRNA) which retained full activity<sup>49</sup>. Immediately thereafter, groundbreaking studies from the Doudna group in parallel with the group of Feng Zhang and George Church adapted the CRISPR/Cas9 system for *in vivo* genome editing in mammalian cells<sup>54-56</sup>. Soon after CRISPR/Cas9 was used by the Jaenisch group to generate mice with multiple KO, conditional KO and reporter genes by zygote injection<sup>57, 58</sup>.

Thus, instead of constant target specific re-engineering of protein modules as needed for ZFNs and TALENs, the Cas9 endonuclease requires only the simple construction of a short RNA molecule for genome editing at a given locus. In addition to its simple low-cost design

this approach can also swiftly be multiplexed to target multiple genes at the same time. As this system was easy to adapt by any biomedical laboratory, CRISPR genome editing revolutionized the field and subsequently Emmanuelle Charpentier and Jennifer Doudna were awarded the 2020 Nobel Prize in Chemistry for its discovery. To date, this technology has been used to modify the genome of virtually all model organisms including fly, worm, zebrafish, frogs, rat, rabbit, pig, cattle, goat, sheep and non-human primates (see Table S1 online for references).



**Figure 1. Mechanism of major genome editing platforms.**

All four major genome editing systems lead to DSBs at the desired locus. These DSBs breaks are either repaired by error-prone end-joining pathways resulting in INDELs or, if a DNA repair template is provided, by HDR. The latter mechanism can be exploited to introduce site-specific mutations into the locus of interest. While meganucleases, ZFN and TALENs rely on protein-DNA interaction for target recognition CRISPR/Cas9 utilizes a dual guide RNA composed of a generic tracrRNA and a specific crRNA.



## Natural and engineered CRISPR systems (2013 – now)

The Cas9 of *Streptococcus pyogenes* (SpCas9) used in the original publication has a simple PAM requirement (NGG) and CRISPR/Cas9 is still by far the most popular programmable Cas nuclease system for genome editing. Nevertheless, researchers have constantly searched for other Cas9 or Cas9-like proteins and developed a number of engineered versions of Cas9 with different properties like alternative PAM requirements, protein size, or substrate specificity to harness them for genome editing<sup>59</sup>.

*In vivo* mutagenesis of specific organs in adult animals as well as gene therapy in humans is most often accomplished by means of viral vectors. The large protein size of SpCas9 (about 1400 amino acids), however, does not allow for delivery using the popular adeno-associated virus system. In search for a smaller Cas9 variants, researchers discovered in 2015 that *Staphylococcus aureus* utilizes a much smaller Cas9 (about 1000 amino acids). This allowed genome editing in specific organs in mice by viral delivery of CRISPR/Cas9<sup>60</sup>. Many other Cas proteins have followed which differ in their protein size, PAM requirement, spacer length and editing specificity. With Cas12a, initially termed Cpf1, an entirely new class of CRISPR proteins was introduced in 2015<sup>61</sup>. This system broadened the applicability of genome editing to TT rich PAM targets as Cas12a uses the PAM sequence TTTV (V equals A, G or C). Only one year later, it was shown to work *in vivo* by the production of KO mice<sup>62, 63</sup>. Previously inaccessible loci could now be edited with this system. Whereas all known CRISPR system until this point targeted DNA, the group of Feng Zhang discovered the CRISPR/Cas13 system, an RNA editing system, in 2017<sup>64</sup>. By targeting RNA, CRISPR/Cas13 can be used to modify the function of a gene by degradation of the mRNA allowing the reduction of a genes function by knock-down instead of a complete removal. Cas13 orthologs have recently also been shown to be effective *in vivo* in several animal embryos including zebrafish and mice<sup>65</sup>.

Apart from harnessing natural Cas proteins, researchers have started to re-engineer the well-characterized Cas9 to develop new variants. These efforts pursued mainly two goals: broadening the range of targetable site by changing PAM specificities and enhancing the fidelity of Cas9. One disadvantage of the CRISPR system are off-target modifications which represent undesired mutations at loci that resemble the on-target sequence. It has been shown that SpCas9 can tolerate several mismatches depending on their distribution and position in the guide sequence<sup>66</sup>. Off-target mutations during genome editing in animals with a short generation cycle like mice is undesirable but can be partially compensated by backcrossing to remove the unwanted mutation. In contrast, off-targets in long-lived animals, like most live stock, and especially during therapeutic intervention in humans must be avoided. Therefore, researchers are still researching for ways to increase the specificity of Cas9. In a first attempt, the Cas9 protein has been used as a tandem, much like ZFNs and TALENs before. To this end one of the two nuclease domains of Cas9 was inactivated leading to a nickase which cuts only one strand of DNA. This approach proved to increase the specificity of the system *in vitro* and *in vivo* in mice<sup>67</sup>. The first high-fidelity protein variant of Cas9 was generated three years later in 2016 by Feng Zhang's group. They used structure-guided engineering in order to change residues in the protein to prevent nonspecific DNA binding<sup>68</sup>. Currently, many more variants have been created which can discriminate even single base pair mismatches<sup>69</sup>. However, none of these versions seem to retain the on-target activity of wild-type SpCas9<sup>70</sup>. Another limitation of the CRISPR system for genome editing is the requirement of a PAM sequence like NGG for SpCas9. This limits the targeting scope of Cas9 resulting in inaccessibility of certain loci. The first Cas9 with an altered and simplified PAM to overcome this limitation was introduced in 2015 by J. Keith Joung's group<sup>71</sup>. This work, performed in zebrafish and human cells, demonstrated that a re-engineered SpCas9 efficiently recognized alternative PAM sequences like NGA. To date re-engineered Cas9 variants can recognize a variety of PAM sequences.


Most recently, a variant with near PAMless activity was constructed although this increased flexibility unfortunately still affects on-target activity<sup>72</sup>.

Another risk of genome editing with nucleases like Cas9 are the undesired effects of DNA DSBs. Although these DSBs facilitate the introduction of foreign DNA they can also lead to undesired DNA modifications and even re-arrangements within the genome which must be avoided, especially in long-lived animals and precision human medicine. To circumvent DNA DSBs, the group of David Liu introduced base editing in 2016<sup>73</sup>. Here, a catalytically inactivated Cas9 is fused to a deaminase enzyme domain. This system allows single-base pair conversion of specific nucleotides, like C to T, without a DSB and without relying on HDR using donor templates. Base editing has now been used in many model organisms like zebrafish, frogs, mice, rats and rabbit but also in live-stock like pigs, goat and sheep and non-human primates (see Table S1 online for references).

Base editors can only convert certain nucleotides and cannot introduce deletions or insertions. To overcome these limitations another exciting CRISPR application was introduced in 2019<sup>74</sup>. Prime editing makes use of a Cas9 nickase fused to a reverse transcriptase. A dual functional prime editor gRNA (pegRNA) guides the Cas9 nickase to the desired locus. In addition, the pegRNA also harbors the template for the reverse transcriptase to copy the intended genetic change into the target DNA, starting from a short primer binding site complementary to the second strand of the target DNA. This system can install specific INDELs and all base-to-base conversions without relying on HDR and DNA DSB. Initially developed *in vitro*, this system has already proven to be applicable to model organisms like mice<sup>75</sup>. Prime editing holds great promises for precise modification in animals and has clinical potential for human health as it shows exceptionally high specificity.

Apart from genome editing, the specific DNA binding capacity of catalytically inactive Cas9 has also led to many other applications *in vitro* and *in vivo* by fusion of different effectors. This has enabled site-specific applications such as gene regulation with transcriptional

effectors, modification of the epigenome by epigenetic modifiers and live cell chromatin imaging by fluorescent proteins<sup>59</sup>. In addition, CRISPR-based technologies have led to numerous other exciting applications, including in agriculture and healthcare, which are beyond the scope of this review<sup>76</sup>.



**Figure 2. Key developments in the history of genome editing.**

DSBs, double-strand breaks; HDR, homology-directed repair; KO, knock-out; PAM, protospacer adjacent motif; TALENs, transcription activator-like effector nucleases; ZFN, zinc finger nucleases.

## Conclusions and future directions

Gene editing has revolutionized biomedical research. Starting from the realization that meganuclease-mediated DSBs enhance integration of foreign DNA, many researchers have searched for an optimal tool to introduce these breaks in the DNA in a sequence specific fashion. Protein engineering led to the use of programmable ZFNs and, shortly thereafter, TALENs, which soon paved the way to simple and robust RNA-guided CRISPR genome editing. Due to its superior applicability, CRISPR has quickly become routine in many

biomedical laboratories. Furthermore, the predominantly used and still most efficient SpCas9 system has been re-engineered for higher specificity and widened range of targetable loci but also applications beyond genome editing. Additionally, many other CRISPR systems have been introduced for genome editing and even other applications.

Due to the high variability of bacteria and archaea, many other CRISPR systems are likely to be discovered in the future. These new variants hold great potential to overcome the current constraints of genome editing. The limitation of PAM availability is a common issue<sup>72</sup>. The discovery of new Cas proteins or intentional re-engineering of known variants without any PAM requirement but retained efficiency would simplify genome editing tremendously. Unintended mutations due to off-target effects are another main obstacle of current CRISPR systems used for genome editing<sup>77</sup>. Substantial efforts have already led to Cas9 variants with enhanced specificity and acceptable trade-off on efficacy. A high-fidelity Cas protein, natural or re-engineered, with retained efficiency has yet to be developed<sup>70</sup>.

All genome editing tools only direct the endogenous repair machinery to a specific locus rather than directly inducing the desired genetic alteration. While off-target mutations can mostly be predicted due to a number of available algorithms, unintended alterations at the on-target locus are still largely unpredictable. Besides small INDELs large and/or complex genetic alterations have been shown to occur including chromosomal translocations and megabase-scale deletion<sup>78</sup>. Even newer generation tools aiming for high precision like prime and base editors are not entirely predictable in their outcome<sup>77</sup>. A consensus on criteria for quality control of genome edited animals will be essential in order to ensure reliable and reproducible research.

Even if applied with rigid quality control to reduce the above-mentioned challenges, the number of animals needed per experiment will likely not be reduced compared to ES cell mutagenesis. Moreover, the ease of use and widespread availability of genome editing tools could even lead to an increase in genetically engineered models generated and accordingly animals used in research. However, the power of genome editing lies in its potential to introduce

mutations directly on desired genetic strain backgrounds and complex existing animal models. This largely avoids extensive animal breeding programs to obtain required allele configurations to an extent unachievable by classical genetic engineering. In addition, the ability for precise alteration of alleles will reflect human diseases more precisely than previously possible and in species most appropriate to the research objectives, ideally being less sentient than classical models. This will help to apply genome editing in line with the concept of the 3Rs<sup>79</sup>.

### **Acknowledgement**

We are grateful to Jan Parker-Thornburg for her valuable comments on the manuscript. We apologize if for space limitations we may have left out original work that deserved citation. Figure 1 was created with BioRender.com.

### **Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

### **Declaration of Conflicting Interests**

The authors declare that there is no conflict of interest.

## References

1. Jaenisch R and Mintz B. Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. *Proc Natl Acad Sci U S A* 1974; 71: 1250-1254. 1974/04/01. DOI: 10.1073/pnas.71.4.1250.
2. Gordon JW and Ruddle FH. Integration and stable germ line transmission of genes injected into mouse pronuclei. *Science* 1981; 214: 1244-1246. 1981/12/11. DOI: 10.1126/science.6272397.
3. Gordon JW, Scangos GA, Plotkin DJ, et al. Genetic transformation of mouse embryos by microinjection of purified DNA. *Proc Natl Acad Sci U S A* 1980; 77: 7380-7384. 1980/12/01. DOI: 10.1073/pnas.77.12.7380.
4. Costantini F and Lacy E. Introduction of a rabbit beta-globin gene into the mouse germ line. *Nature* 1981; 294: 92-94. 1981/11/05. DOI: 10.1038/294092a0.
5. Brinster RL, Chen HY, Trumbauer M, et al. Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. *Cell* 1981; 27: 223-231. 1981/11/01. DOI: 10.1016/0092-8674(81)90376-7.
6. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci U S A* 1981; 78: 7634-7638. 1981/12/01. DOI: 10.1073/pnas.78.12.7634.
7. Evans MJ and Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. *Nature* 1981; 292: 154-156. 1981/07/09. DOI: 10.1038/292154a0.
8. Bradley A, Evans M, Kaufman MH, et al. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. *Nature* 1984; 309: 255-256. 1984/05/17. DOI: 10.1038/309255a0.
9. Doetschman T, Gregg RG, Maeda N, et al. Targetted correction of a mutant HPRT gene in mouse embryonic stem cells. *Nature* 1987; 330: 576-578. 1987/12/10. DOI: 10.1038/330576a0.
10. Thomas KR and Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. *Cell* 1987; 51: 503-512. 1987/11/06. DOI: 10.1016/0092-8674(87)90646-5.
11. Capecchi MR. Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century. *Nature reviews Genetics* 2005; 6: 507-512. 2005/06/03. DOI: 10.1038/nrg1619.
12. Gu H, Marth JD, Orban PC, et al. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. *Science* 1994; 265: 103-106. 1994/07/01. DOI: 10.1126/science.8016642.
13. Brinster RL, Braun RE, Lo D, et al. Targeted correction of a major histocompatibility class II E alpha gene by DNA microinjected into mouse eggs. *Proc Natl Acad Sci U S A* 1989; 86: 7087-7091. 1989/09/01. DOI: 10.1073/pnas.86.18.7087.
14. Martello G and Smith A. The nature of embryonic stem cells. *Annu Rev Cell Dev Biol* 2014; 30: 647-675. 2014/10/08. DOI: 10.1146/annurev-cellbio-100913-013116.
15. Choulika A, Perrin A, Dujon B, et al. Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of *Saccharomyces cerevisiae*. *Molecular and cellular biology* 1995; 15: 1968-1973. 1995/04/01. DOI: 10.1128/mcb.15.4.1968.
16. Rouet P, Smih F and Jasin M. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. *Molecular and cellular biology* 1994; 14: 8096-8106. 1994/12/01. DOI: 10.1128/mcb.14.12.8096.

17. Cohen-Tannoudji M, Robine S, Chouluka A, et al. I-SceI-induced gene replacement at a natural locus in embryonic stem cells. *Molecular and cellular biology* 1998; 18: 1444-1448. 1998/03/06. DOI: 10.1128/mcb.18.3.1444.
18. Jacquier A and Dujon B. An intron-encoded protein is active in a gene conversion process that spreads an intron into a mitochondrial gene. *Cell* 1985; 41: 383-394. 1985/06/01. DOI: 10.1016/s0092-8674(85)80011-8.
19. Stoddard BL. Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification. *Structure* 2011; 19: 7-15. 2011/01/12. DOI: 10.1016/j.str.2010.12.003.
20. Grizot S, Smith J, Daboussi F, et al. Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. *Nucleic Acids Res* 2009; 37: 5405-5419. 2009/07/09. DOI: 10.1093/nar/gkp548.
21. Ashworth J, Havranek JJ, Duarte CM, et al. Computational redesign of endonuclease DNA binding and cleavage specificity. *Nature* 2006; 441: 656-659. 2006/06/02. DOI: 10.1038/nature04818.
22. Menoret S, Fontaniere S, Jantz D, et al. Generation of Rag1-knockout immunodeficient rats and mice using engineered meganucleases. *FASEB J* 2013; 27: 703-711. 2012/11/15. DOI: 10.1096/fj.12-219907.
23. Miller J, McLachlan AD and Klug A. Repetitive zinc-binding domains in the protein transcription factor IIIA from *Xenopus* oocytes. *EMBO J* 1985; 4: 1609-1614. 1985/06/01.
24. Klug A. The discovery of zinc fingers and their applications in gene regulation and genome manipulation. *Annu Rev Biochem* 2010; 79: 213-231. 2010/03/03. DOI: 10.1146/annurev-biochem-010909-095056.
25. Kim YG, Cha J and Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. *Proc Natl Acad Sci U S A* 1996; 93: 1156-1160. 1996/02/06. DOI: 10.1073/pnas.93.3.1156.
26. Bibikova M, Carroll D, Segal DJ, et al. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. *Molecular and cellular biology* 2001; 21: 289-297. 2000/12/13. DOI: 10.1128/MCB.21.1.289-297.2001.
27. Bibikova M, Beumer K, Trautman JK, et al. Enhancing gene targeting with designed zinc finger nucleases. *Science* 2003; 300: 764. 2003/05/06. DOI: 10.1126/science.1079512.
28. Porteus MH and Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. *Science* 2003; 300: 763. 2003/05/06. DOI: 10.1126/science.1078395.
29. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. *Nature* 2005; 435: 646-651. 2005/04/05. DOI: 10.1038/nature03556.
30. Urnov FD. Genome Editing B.C. (Before CRISPR): Lasting Lessons from the "Old Testament". *CRISPR J* 2018; 1: 34-46. 2018/02/01. DOI: 10.1089/crispr.2018.29007.fyu.
31. Doyon Y, McCammon JM, Miller JC, et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. *Nat Biotechnol* 2008; 26: 702-708. 2008/05/27. DOI: 10.1038/nbt1409.
32. Meng X, Noyes MB, Zhu LJ, et al. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. *Nat Biotechnol* 2008; 26: 695-701. 2008/05/27. DOI: 10.1038/nbt1398.



33. Santiago Y, Chan E, Liu PQ, et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. *Proc Natl Acad Sci U S A* 2008; 105: 5809-5814. 2008/03/25. DOI: 10.1073/pnas.0800940105.
34. Geurts AM, Cost GJ, Freyvert Y, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. *Science* 2009; 325: 433. 2009/07/25. DOI: 10.1126/science.1172447.
35. Christian M, Cermak T, Doyle EL, et al. Targeting DNA double-strand breaks with TAL effector nucleases. *Genetics* 2010; 186: 757-761. 2010/07/28. DOI: 10.1534/genetics.110.120717.
36. Miller JC, Tan S, Qiao G, et al. A TALE nuclease architecture for efficient genome editing. *Nat Biotechnol* 2011; 29: 143-148. 2010/12/24. DOI: 10.1038/nbt.1755.
37. Bogdanove AJ and Voytas DF. TAL effectors: customizable proteins for DNA targeting. *Science* 2011; 333: 1843-1846. 2011/10/01. DOI: 10.1126/science.1204094.
38. Ishino Y, Shinagawa H, Makino K, et al. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in *Escherichia coli*, and identification of the gene product. *J Bacteriol* 1987; 169: 5429-5433. 1987/12/01. DOI: 10.1128/jb.169.12.5429-5433.1987.
39. Mojica FJ, Diez-Villasenor C, Soria E, et al. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. *Mol Microbiol* 2000; 36: 244-246. 2000/04/12. DOI: 10.1046/j.1365-2958.2000.01838.x.
40. Jansen R, Embden JD, Gaastra W, et al. Identification of genes that are associated with DNA repeats in prokaryotes. *Mol Microbiol* 2002; 43: 1565-1575. 2002/04/16. DOI: 10.1046/j.1365-2958.2002.02839.x.
41. Bolotin A, Quinquis B, Sorokin A, et al. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. *Microbiology* 2005; 151: 2551-2561. 2005/08/05. DOI: 10.1099/mic.0.28048-0.
42. Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, et al. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. *J Mol Evol* 2005; 60: 174-182. 2005/03/29. DOI: 10.1007/s00239-004-0046-3.
43. Pourcel C, Salvignol G and Vergnaud G. CRISPR elements in *Yersinia pestis* acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. *Microbiology* 2005; 151: 653-663. 2005/03/11. DOI: 10.1099/mic.0.27437-0.
44. Barrangou R, Fremaux C, Deveau H, et al. CRISPR provides acquired resistance against viruses in prokaryotes. *Science* 2007; 315: 1709-1712. 2007/03/24. DOI: 10.1126/science.1138140.
45. Brouns SJ, Jore MM, Lundgren M, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. *Science* 2008; 321: 960-964. 2008/08/16. DOI: 10.1126/science.1159689.
46. Marraffini LA and Sontheimer EJ. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. *Science* 2008; 322: 1843-1845. 2008/12/20. DOI: 10.1126/science.1165771.
47. Mojica FJM, Diez-Villasenor C, Garcia-Martinez J, et al. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. *Microbiology* 2009; 155: 733-740. 2009/02/28. DOI: 10.1099/mic.0.023960-0.
48. Deveau H, Barrangou R, Garneau JE, et al. Phage response to CRISPR-encoded resistance in *Streptococcus thermophilus*. *J Bacteriol* 2008; 190: 1390-1400. 2007/12/11. DOI: 10.1128/JB.01412-07.

49. Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* 2012; 337: 816-821. 2012/06/30. DOI: 10.1126/science.1225829.
50. Marraffini LA and Sontheimer EJ. Self versus non-self discrimination during CRISPR RNA-directed immunity. *Nature* 2010; 463: 568-571. 2010/01/15. DOI: 10.1038/nature08703.
51. Sapranaukas R, Gasiunas G, Fremaux C, et al. The *Streptococcus thermophilus* CRISPR/Cas system provides immunity in *Escherichia coli*. *Nucleic Acids Res* 2011; 39: 9275-9282. 2011/08/05. DOI: 10.1093/nar/gkr606.
52. Deltcheva E, Chylinski K, Sharma CM, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature* 2011; 471: 602-607. 2011/04/02. DOI: 10.1038/nature09886.
53. Gasiunas G, Barrangou R, Horvath P, et al. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc Natl Acad Sci U S A* 2012; 109: E2579-2586. 2012/09/06. DOI: 10.1073/pnas.1208507109.
54. Jinek M, East A, Cheng A, et al. RNA-programmed genome editing in human cells. *eLife* 2013; 2: e00471. 2013/02/07. DOI: 10.7554/eLife.00471.
55. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. *Science* 2013; 339: 819-823. DOI: 10.1126/science.1231143.
56. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. *Science* 2013; 339: 823-826. 2013/01/05. DOI: 10.1126/science.1232033.
57. Yang H, Wang H, Shivalila CS, et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. *Cell* 2013; 154: 1370-1379. DOI: 10.1016/j.cell.2013.08.022.
58. Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* 2013; 153: 910-918. 2013/05/07. DOI: 10.1016/j.cell.2013.04.025.
59. Adli M. The CRISPR tool kit for genome editing and beyond. *Nat Commun* 2018; 9: 1911. 2018/05/17. DOI: 10.1038/s41467-018-04252-2.
60. Ran FA, Cong L, Yan WX, et al. In vivo genome editing using *Staphylococcus aureus* Cas9. *Nature* 2015; 520: 186-191. 2015/04/02. DOI: 10.1038/nature14299.
61. Zetsche B, Gootenberg JS, Abudayyeh OO, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell* 2015; 163: 759-771. 2015/10/01. DOI: 10.1016/j.cell.2015.09.038.
62. Kim Y, Cheong SA, Lee JG, et al. Generation of knockout mice by Cpf1-mediated gene targeting. *Nat Biotechnol* 2016. DOI: 10.1038/nbt.3614.
63. Hur JK, Kim K, Been KW, et al. Targeted mutagenesis in mice by electroporation of Cpf1 ribonucleoproteins. *Nat Biotechnol* 2016; 34: 807-808. DOI: 10.1038/nbt.3596.
64. Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al. RNA targeting with CRISPR-Cas13. *Nature* 2017; 550: 280-284. 2017/10/05. DOI: 10.1038/nature24049.
65. Kushawah G, Hernandez-Huertas L, Abugattas-Nunez Del Prado J, et al. CRISPR-Cas13d Induces Efficient mRNA Knockdown in Animal Embryos. *Dev Cell* 2020 2020/08/10. DOI: 10.1016/j.devcel.2020.07.013.
66. Hsu PD, Scott DA, Weinstein JA, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat Biotechnol* 2013; 31: 827-832. 2013/07/23. DOI: 10.1038/nbt.2647.
67. Ran FA, Hsu PD, Lin CY, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. *Cell* 2013; 154: 1380-1389. 2013/09/03. DOI: 10.1016/j.cell.2013.08.021.

68. Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered Cas9 nucleases with improved specificity. *Science* 2016; 351: 84-88. 2015/12/03. DOI: 10.1126/science.aad5227.
69. Schmid-Burgk JL, Gao L, Li D, et al. Highly Parallel Profiling of Cas9 Variant Specificity. *Molecular cell* 2020 2020/03/19. DOI: 10.1016/j.molcel.2020.02.023.
70. Kim N, Kim HK, Lee S, et al. Prediction of the sequence-specific cleavage activity of Cas9 variants. *Nat Biotechnol* 2020 2020/06/10. DOI: 10.1038/s41587-020-0537-9.
71. Kleinstiver BP, Prew MS, Tsai SQ, et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. *Nature* 2015; 523: 481-485. 2015/06/23. DOI: 10.1038/nature14592.
72. Walton RT, Christie KA, Whittaker MN, et al. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. *Science* 2020 2020/03/29. DOI: 10.1126/science.aba8853.
73. Komor AC, Kim YB, Packer MS, et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* 2016; 533: 420-424. 2016/04/21. DOI: 10.1038/nature17946.
74. Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature* 2019 2019/10/22. DOI: 10.1038/s41586-019-1711-4.
75. Liu Y, Li X, He S, et al. Efficient generation of mouse models with the prime editing system. *Cell Discov* 2020; 6: 27. 2020/05/01. DOI: 10.1038/s41421-020-0165-z.
76. Zhang F. Development of CRISPR-Cas systems for genome editing and beyond. *Quarterly Reviews of Biophysics* 2019; 52. DOI: 10.1017/s0033583519000052.
77. Anzalone AV, Koblan LW and Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. *Nat Biotechnol* 2020 2020/06/24. DOI: 10.1038/s41587-020-0561-9.
78. Burgio G and Teboul L. Anticipating and Identifying Collateral Damage in Genome Editing. *Trends Genet* 2020; 36: 905-914. 2020/10/12. DOI: 10.1016/j.tig.2020.09.011.
79. Russell WMS and Burch RL. *The principles of humane experimental technique*. London,: Methuen, 1959, p.238 p.

# Supplementary material for

## History of genome editing - from meganucleases to CRISPR

Simon E. Tröder and Branko Zevnik

**Table S1.** Supplementary references for *in vivo* genome editing

Method	Species	Reference
ZFN	mouse	1, 2
	rat	3
	rabbit	4
	pig	5, 6
	cattle	7, 8
TALEN	worm	9
	zebrafish	10, 11
	frog	12
	rat	13
	mouse	14-16
	rabbit	17
	pig	18, 19
	goat	20
	sheep	21
	cattle	21
	non-human primate	22
CRISPR/Cas9	fly	23
	worm	24
	zebrafish	25
	frog	26
	rat	27
	rabbit	28
	pig	29
	cattle	30
	goat	31
	sheep	32
	non-human primate	33
CRISPR base editing	zebrafish	34
	frog	35
	mouse	36
	rat	37, 38
	rabbit	39
	pig	40
	goat	41
	sheep	42
	non-human primate	43

## Supplementary references

1. Meyer M, de Angelis MH, Wurst W, et al. Gene targeting by homologous recombination in mouse zygotes mediated by zinc-finger nucleases. *Proc Natl Acad Sci U S A* 2010; 107: 15022-15026. 2010/08/06. DOI: 10.1073/pnas.1009424107.
2. Carbery ID, Ji D, Harrington A, et al. Targeted genome modification in mice using zinc-finger nucleases. *Genetics* 2010; 186: 451-459. 2010/07/16. DOI: 10.1534/genetics.110.117002.
3. Geurts AM, Cost GJ, Freyvert Y, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. *Science* 2009; 325: 433. 2009/07/25. DOI: 10.1126/science.1172447.
4. Flisikowska T, Thorey IS, Offner S, et al. Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. *PloS one* 2011; 6: e21045. 2011/06/23. DOI: 10.1371/journal.pone.0021045.
5. Hauschild J, Petersen B, Santiago Y, et al. Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases. *Proc Natl Acad Sci U S A* 2011; 108: 12013-12017. 2011/07/07. DOI: 10.1073/pnas.1106422108.
6. Whyte JJ, Zhao J, Wells KD, et al. Gene targeting with zinc finger nucleases to produce cloned eGFP knockout pigs. *Mol Reprod Dev* 2011; 78: 2. 2011/01/27. DOI: 10.1002/mrd.21271.
7. Liu X, Wang Y, Guo W, et al. Zinc-finger nickase-mediated insertion of the lysostaphin gene into the beta-casein locus in cloned cows. *Nat Commun* 2013; 4: 2565. 2013/10/15. DOI: 10.1038/ncomms3565.
8. Yu S, Luo J, Song Z, et al. Highly efficient modification of beta-lactoglobulin (BLG) gene via zinc-finger nucleases in cattle. *Cell research* 2011; 21: 1638-1640. 2011/09/14. DOI: 10.1038/cr.2011.153.
9. Wood AJ, Lo TW, Zeitler B, et al. Targeted genome editing across species using ZFNs and TALENs. *Science* 2011; 333: 307. 2011/06/28. DOI: 10.1126/science.1207773.
10. Huang P, Xiao A, Zhou M, et al. Heritable gene targeting in zebrafish using customized TALENs. *Nat Biotechnol* 2011; 29: 699-700. 2011/08/09. DOI: 10.1038/nbt.1939.
11. Sander JD, Cade L, Khayter C, et al. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. *Nat Biotechnol* 2011; 29: 697-698. 2011/08/09. DOI: 10.1038/nbt.1934.
12. Lei Y, Guo X, Liu Y, et al. Efficient targeted gene disruption in *Xenopus* embryos using engineered transcription activator-like effector nucleases (TALENs). *Proc Natl Acad Sci U S A* 2012; 109: 17484-17489. 2012/10/10. DOI: 10.1073/pnas.1215421109.
13. Tesson L, Usal C, Menoret S, et al. Knockout rats generated by embryo microinjection of TALENs. *Nat Biotechnol* 2011; 29: 695-696. 2011/08/09. DOI: 10.1038/nbt.1940.
14. Panda SK, Wefers B, Ortiz O, et al. Highly efficient targeted mutagenesis in mice using TALENs. *Genetics* 2013; 195: 703-713. 2013/08/28. DOI: 10.1534/genetics.113.156570.
15. Sung YH, Baek IJ, Kim DH, et al. Knockout mice created by TALEN-mediated gene targeting. *Nat Biotechnol* 2013; 31: 23-24. 2013/01/11. DOI: 10.1038/nbt.2477.

16. Wefers B, Panda SK, Ortiz O, et al. Generation of targeted mouse mutants by embryo microinjection of TALEN mRNA. *Nature protocols* 2013; 8: 2355-2379. 2013/11/02. DOI: 10.1038/nprot.2013.142.
17. Song J, Zhong J, Guo X, et al. Generation of RAG 1- and 2-deficient rabbits by embryo microinjection of TALENs. *Cell research* 2013; 23: 1059-1062. 2013/07/10. DOI: 10.1038/cr.2013.85.
18. Carlson DF, Tan W, Lillico SG, et al. Efficient TALEN-mediated gene knockout in livestock. *Proc Natl Acad Sci U S A* 2012; 109: 17382-17387. 2012/10/03. DOI: 10.1073/pnas.1211446109.
19. Lillico SG, Proudfoot C, Carlson DF, et al. Live pigs produced from genome edited zygotes. *Sci Rep* 2013; 3: 2847. 2013/10/11. DOI: 10.1038/srep02847.
20. Cui C, Song Y, Liu J, et al. Gene targeting by TALEN-induced homologous recombination in goats directs production of beta-lactoglobulin-free, high-human lactoferrin milk. *Sci Rep* 2015; 5: 10482. 2015/05/23. DOI: 10.1038/srep10482.
21. Proudfoot C, Carlson DF, Huddart R, et al. Genome edited sheep and cattle. *Transgenic research* 2015; 24: 147-153. 2014/09/11. DOI: 10.1007/s11248-014-9832-x.
22. Liu H, Chen Y, Niu Y, et al. TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. *Cell Stem Cell* 2014; 14: 323-328. 2014/02/18. DOI: 10.1016/j.stem.2014.01.018.
23. Bassett AR, Tibbit C, Ponting CP, et al. Highly efficient targeted mutagenesis of *Drosophila* with the CRISPR/Cas9 system. *Cell Rep* 2013; 4: 220-228. 2013/07/06. DOI: 10.1016/j.celrep.2013.06.020.
24. Friedland AE, Tzur YB, Esvelt KM, et al. Heritable genome editing in *C. elegans* via a CRISPR-Cas9 system. *Nature methods* 2013; 10: 741-743. 2013/07/03. DOI: 10.1038/nmeth.2532.
25. Hwang WY, Fu Y, Reyon D, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. *Nat Biotechnol* 2013; 31: 227-229. 2013/01/31. DOI: 10.1038/nbt.2501.
26. Nakayama T, Fish MB, Fisher M, et al. Simple and efficient CRISPR/Cas9-mediated targeted mutagenesis in *Xenopus tropicalis*. *Genesis* 2013; 51: 835-843. 2013/10/15. DOI: 10.1002/dvg.22720.
27. Li W, Teng F, Li T, et al. Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems. *Nat Biotechnol* 2013; 31: 684-686. 2013/08/10. DOI: 10.1038/nbt.2652.
28. Yang D, Xu J, Zhu T, et al. Effective gene targeting in rabbits using RNA-guided Cas9 nucleases. *J Mol Cell Biol* 2014; 6: 97-99. 2014/01/10. DOI: 10.1093/jmcb/mjt047.
29. Hai T, Teng F, Guo R, et al. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. *Cell research* 2014; 24: 372-375. 2014/02/01. DOI: 10.1038/cr.2014.11.
30. Bevacqua RJ, Fernandez-Martin R, Savy V, et al. Efficient edition of the bovine PRNP prion gene in somatic cells and IVF embryos using the CRISPR/Cas9 system. *Theriogenology* 2016; 86: 1886-1896 e1881. 2016/08/28. DOI: 10.1016/j.theriogenology.2016.06.010.
31. Wang X, Yu H, Lei A, et al. Generation of gene-modified goats targeting MSTN and FGF5 via zygote injection of CRISPR/Cas9 system. *Sci Rep* 2015; 5: 13878. 2015/09/12. DOI: 10.1038/srep13878.

32. Crispo M, Mulet AP, Tesson L, et al. Efficient Generation of Myostatin Knock-Out Sheep Using CRISPR/Cas9 Technology and Microinjection into Zygotes. *PloS one* 2015; 10: e0136690. 2015/08/26. DOI: 10.1371/journal.pone.0136690.
33. Niu Y, Shen B, Cui Y, et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. *Cell* 2014; 156: 836-843. 2014/02/04. DOI: 10.1016/j.cell.2014.01.027.
34. Zhang Y, Qin W, Lu X, et al. Programmable base editing of zebrafish genome using a modified CRISPR-Cas9 system. *Nat Commun* 2017; 8: 118. 2017/07/26. DOI: 10.1038/s41467-017-00175-6.
35. Park DS, Yoon M, Kweon J, et al. Targeted Base Editing via RNA-Guided Cytidine Deaminases in *Xenopus laevis* Embryos. *Mol Cells* 2017; 40: 823-827. 2017/11/28. DOI: 10.14348/molcells.2017.0262.
36. Kim K, Ryu SM, Kim ST, et al. Highly efficient RNA-guided base editing in mouse embryos. *Nat Biotechnol* 2017; 35: 435-437. 2017/03/01. DOI: 10.1038/nbt.3816.
37. Ma Y, Yu L, Zhang X, et al. Highly efficient and precise base editing by engineered dCas9-guide tRNA adenosine deaminase in rats. *Cell Discov* 2018; 4: 39. 2018/07/25. DOI: 10.1038/s41421-018-0047-9.
38. Yang L, Zhang X, Wang L, et al. Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants. *Protein Cell* 2018; 9: 814-819. 2018/08/02. DOI: 10.1007/s13238-018-0568-x.
39. Liu Z, Chen M, Chen S, et al. Highly efficient RNA-guided base editing in rabbit. *Nat Commun* 2018; 9: 2717. 2018/07/15. DOI: 10.1038/s41467-018-05232-2.
40. Xie J, Ge W, Li N, et al. Efficient base editing for multiple genes and loci in pigs using base editors. *Nat Commun* 2019; 10: 2852. 2019/06/30. DOI: 10.1038/s41467-019-10421-8.
41. Li G, Zhou S, Li C, et al. Base pair editing in goat: nonsense codon introgression into FGF5 results in longer hair. *The FEBS journal* 2019; 286: 4675-4692. 2019/07/06. DOI: 10.1111/febs.14983.
42. Zhou S, Cai B, He C, et al. Programmable Base Editing of the Sheep Genome Revealed No Genome-Wide Off-Target Mutations. *Front Genet* 2019; 10: 215. 2019/04/02. DOI: 10.3389/fgene.2019.00215.
43. Zhang W, Aida T, Del Rosario RCH, et al. Multiplex precise base editing in cynomolgus monkeys. *Nat Commun* 2020; 11: 2325. 2020/05/13. DOI: 10.1038/s41467-020-16173-0.